Aimmune Therapeutics Inc. (NASDAQ:AIMT)‘s stock had its “overweight” rating reiterated by equities researchers at Piper Jaffray Cos. in a report issued on Friday. They currently have a $40.00 price target on the stock, up from their prior price target of $38.00. Piper Jaffray Cos.’s target price suggests a potential upside of 60.06% from the company’s current price.

AIMT has been the subject of several other reports. Credit Suisse Group AG reiterated a “buy” rating and set a $35.00 target price on shares of Aimmune Therapeutics in a research note on Friday, August 19th. Wedbush reiterated a “buy” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Wednesday, August 24th. JMP Securities started coverage on Aimmune Therapeutics in a research note on Monday, September 26th. They set an “outperform” rating and a $30.00 target price for the company. Finally, Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 19th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $32.60.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics (NASDAQ:AIMT) opened at 24.99 on Friday. Aimmune Therapeutics has a 52 week low of $9.77 and a 52 week high of $27.31. The firm’s market capitalization is $1.06 billion. The firm has a 50-day moving average of $18.97 and a 200 day moving average of $14.94.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Monday, November 14th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.08. Analysts predict that Aimmune Therapeutics will post ($1.81) earnings per share for the current year.

In related news, insider Mary M. Rozenman sold 30,000 shares of the firm’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $16.80, for a total transaction of $504,000.00. Following the transaction, the insider now directly owns 30,000 shares in the company, valued at $504,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mary M. Rozenman sold 25,000 shares of the firm’s stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $16.80, for a total value of $420,000.00. Following the transaction, the insider now owns 25,000 shares in the company, valued at $420,000. The disclosure for this sale can be found here. Corporate insiders own 24.56% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the company. BlackRock Investment Management LLC raised its stake in shares of Aimmune Therapeutics by 149.0% in the second quarter. BlackRock Investment Management LLC now owns 96,041 shares of the company’s stock valued at $1,039,000 after buying an additional 57,463 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Aimmune Therapeutics by 8.9% in the second quarter. Vanguard Group Inc. now owns 1,339,847 shares of the company’s stock valued at $14,497,000 after buying an additional 109,457 shares in the last quarter. TLP Group LLC raised its stake in shares of Aimmune Therapeutics by 0.6% in the second quarter. TLP Group LLC now owns 2,833,285 shares of the company’s stock valued at $30,656,000 after buying an additional 17,000 shares in the last quarter. Nationwide Fund Advisors raised its stake in shares of Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock valued at $183,000 after buying an additional 9,495 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Aimmune Therapeutics by 150.5% in the second quarter. JPMorgan Chase & Co. now owns 105,975 shares of the company’s stock valued at $1,147,000 after buying an additional 63,675 shares in the last quarter. Hedge funds and other institutional investors own 71.11% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.